Sitafloxacin: Difference between revisions
m Protected "Sitafloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Sitafloxacin''' (also called '''DU-6859a''') is a [[fluoroquinolone]] antibiotic that shows promise in the treatment of [[Buruli ulcer]]. The molecule was identified by [[Daiichi Sankyo Co.|Daiichi Pharmaceutical Co. Ltd]], who have also brought [[ofloxacin]] and [[levofloxacin]] to the market. Sitafloxacin is currently under development in [[Japan]]. | '''Sitafloxacin''' (also called '''DU-6859a''') is a [[fluoroquinolone]] antibiotic that shows promise in the treatment of [[Buruli ulcer]]. The molecule was identified by [[Daiichi Sankyo Co.|Daiichi Pharmaceutical Co. Ltd]], who have also brought [[ofloxacin]] and [[levofloxacin]] to the market. Sitafloxacin is currently under development in [[Japan]]. | ||
| Line 33: | Line 33: | ||
[[Category:Fluoroquinolone antibiotics]] | [[Category:Fluoroquinolone antibiotics]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:05, 20 August 2012
|
WikiDoc Resources for Sitafloxacin |
|
Articles |
|---|
|
Most recent articles on Sitafloxacin Most cited articles on Sitafloxacin |
|
Media |
|
Powerpoint slides on Sitafloxacin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Sitafloxacin at Clinical Trials.gov Clinical Trials on Sitafloxacin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Sitafloxacin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Sitafloxacin Discussion groups on Sitafloxacin Patient Handouts on Sitafloxacin Directions to Hospitals Treating Sitafloxacin Risk calculators and risk factors for Sitafloxacin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Sitafloxacin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Sitafloxacin (also called DU-6859a) is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Pharmaceutical Co. Ltd, who have also brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently under development in Japan.